|Bid||1.87 x 1000|
|Ask||1.88 x 1000|
|Day's Range||1.78 - 1.92|
|52 Week Range||0.96 - 2.75|
|Beta (3Y Monthly)||3.38|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 7, 2017 - Aug 11, 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||3.67|
NEW YORK, NY / ACCESSWIRE / October 15, 2018 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive report on Novavax, Inc. (NVAX), a biotechnology company focused on the discovery and development of innovative vaccines to prevent serious respiratory diseases. The company's products are targeted for worldwide markets and its core commercial team is already laying the groundwork before launching with government policymakers, provider, payers, associations, advocates and opinion leaders in advance of regulatory approval.
The healthcare industry can be precarious for stocks of large companies, much less penny stocks. None of these are new companies – they have made progress in developing products and finding the marketing outlets that are needed to sustain them. Because of the higher risk, investors should continuously perform due diligence.
A Wall Street analyst turned bullish -- and the market responded in kind. But investors may want to consider the binary nature of this biopharma stock.
HENDERSON, NV / ACCESSWIRE / October 10, 2018 / The biotech market is moved by events and announcements. There are a few major events currently impacting the companies highlighted below. Propanc Biopharma, ...
According to Novavax’s Q2 2018 earnings conference call, ~3.9 million babies are born annually in the United States. About 70% of them are afflicted with RSV (respiratory syncytial virus) before the age of one year. Novavax (NVAX) thus expects all infants up to six months of age to be exposed to RSV.
Based on this progress, Novavax expects to release final efficacy data in the first quarter of 2019. According to Novavax’s second-quarter 2018 earnings conference call, since the FDA has granted fast-track designation to the ResVax program, the company becomes eligible for priority review of its BLA. The above diagram is a snapshot of Novavax’s investor presentation, which shows that 85% or more of infant hospitalizations could have been prevented if they had been immunized with the RSV (respiratory syncytial virus) vaccine.
Novavax (NVAX) has reported 2018 YTD (year-to-date) returns of 70.16%. In the second quarter of 2018, Novavax reported revenues of $10.78 million, which is a YoY rise of 60.2%. According to a Novavax investor presentation, RSV (respiratory syncytial virus) infection is the second leading cause of death globally in children younger than one year of age, just behind malaria.
Novavax (NVAX) is a clinical stage biotechnology company focused on the development of vaccines targeting infectious diseases with significant unmet demand. The stock rose 11.29%, from $1.86 on October 1 to $2.07 on October 5, mainly due to updates to the company’s research pipeline at the Ladenburg Thalmann 2018 Healthcare Conference on October 2 and the 2018 Cantor Global Healthcare Conference n October 3. Novavax is currently trading 115.22% higher than its 52-week low of $0.96 and 24.73% lower than its 52-week high of $2.75.
As Novavax, Inc. (NASDAQ: NVAX ) approaches two key dates in its pipeline, bulls are preparing to profit. The Rating B Riley FBR analysts George Zavoico and Dylan Dupuis maintained a Buy rating on Novavax ...
Investors need to pay close attention to Novavax (NVAX) stock based on the movements in the options market lately.
NEW YORK, NY / ACCESSWIRE / October 4, 2018 / Major U.S. markets closed up on Wednesday, with the Dow Jones hitting a record high for the 15th time this year on upbeat economic data. However, market gains ...
GAITHERSBURG, Md., Oct. 02, 2018 -- Novavax, Inc. (NASDAQ: NVAX) today announced that its representatives will share data from its RSV F vaccine program via oral and poster.
GAITHERSBURG, Md., Sept. 26, 2018-- Novavax, Inc. today announced that it will present at the Ladenburg Thalmann 2018 Healthcare Conference and the Cantor Global Healthcare Conference 2018, both in the ...
In September 2018, of the total eight analysts covering Novavax (NVAX), five analysts have given Novavax stock a “buy” or higher rating, and three analysts have given Novavax a “hold” rating. The mean rating for Novavax stock is 2.13 with a target price of $3.86, implying an upside potential of 141.3% over Novavax’s closing price of $1.60 as of September 21.
The company is a clinical stage biotechnology company with a focus on recombinant nanoparticle vaccines and adjuvants. Novavax’s product pipeline is mainly focused on respiratory syncytial virus (or RSV) and seasonal influenza. Its RSV programs are targeted at three different populations: older adults, pediatrics, and infants via maternal immunization.
Novavax (NVAX) incurred general and administrative expenses of $8.22 million in the second quarter of 2018 as compared with $8.94 million in the second quarter of 2017. Novavax’s operating loss was $41.99 million in the second quarter of 2018 as compared with an operating loss of $41.47 million in the second quarter of 2017. Novavax’s interest expense was relatively flat at $3.4 million in the second quarter of 2018 as compared with $3.52 million in the second quarter of 2017.
Novavax, Inc. (NVAX) today announced the initiation of a Phase 2 dose and formulation confirmation clinical trial in older adults of NanoFlu, its nanoparticle seasonal influenza vaccine candidate. “Initiating this Phase 2 clinical trial of NanoFlu is an important milestone for Novavax,” said Stanley C. Erck, President and Chief Executive Officer of Novavax.
Novavax, Inc. (NASDAQ: NVAX ) has fallen 31 percent over the last six months, mirroring waning investor excitement over a coming pivotal trial. Amid the heavy sell-off, one analyst sees a buying opportunity ...
Shares of Novavax Inc. soared 12% in premarket trade Friday, after J.P. Morgan analyst Eric Joseph swung to bullish from bearish, citing a favorable risk-reward investment profile ahead of pivotal trial data on its RSV treatment for infants, due out in the first quarter of 2019. Joseph raised his rating two notches to overweight from underweight. He said the shares have already pulled back sharply from recent highs on "receding expectations" regarding the trial outcome. As a result, he sees 50% to over 100% potential upside in the stock after the results, and about an 80% downside risk on a trial failure, but that is viewed as a "less likely" event. "Looking beyond the phase 3 readout, we believe positive PREPARE data would support broader development to additional at-risk populations and their inclusion in the model (pediatric patients under 2yo)," Joseph wrote in a note to clients. The stock had tumbled 39% from the Feb. 20 17-month closing high of $2.42. Over the same time, the iShares Nasdaq Biotechnology ETF has climbed 9.2% and the S&P 500 has advanced 7.9%.